LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD)Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: Updated 2015Seattle, WAGlobal Initiative for Chronic Obstructive Lung Disease (GOLD)2015 Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015_Feb18.pdfAccessed March 14, 2015
   Google Scholar
• BlasiFCesanaGContiSThe clinical and economic impact of exacerbations of chronic obstructive pulmonary disease: a cohort of hospitalized patientsPLoS One201496e10122824971791
   PubMed Web of Science ®Google Scholar
• MiravitllesMSicrasACrespoCCosts of chronic obstructive pulmonary disease in relation to compliance with guidelines: a study in the primary care settingTher Adv Respir Dis20137313915023653458
   PubMed Web of Science ®Google Scholar
• Rutten-van MölkenMPGoossensLMCost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issuesPharmacoeconomics201230427130222409290
   PubMed Web of Science ®Google Scholar
• CalverleyPPauwelsRVestboJTRial of Inhaled STeroids ANd long-acting beta2 agonists study groupCombined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialLancet2003361935644945612583942
   PubMed Web of Science ®Google Scholar
• JonesPWWillitsLRBurgePSCalverleyPMInhaled Steroids in Obstructive Lung Disease in Europe study investigatorsDisease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbationsEur Respir J2003211687312570111
   PubMed Web of Science ®Google Scholar
• MahlerDAWirePHorstmanDEffectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200216681084109112379552
   PubMed Web of Science ®Google Scholar
• JochmannANeubauerFMiedingerDSchafrothSTammMLeuppiJDGeneral practitioner’s adherence to the COPD GOLD guidelines: baseline data of the Swiss COPD Cohort StudySwiss Med Wkly Epub2010421
   Web of Science ®Google Scholar
• SuissaSBarnesPJInhaled corticosteroids in COPD: the case againstEur Respir J2009341131619567599
   PubMed Web of Science ®Google Scholar
• CazzolaMMolimardMThe scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPDPulm Pharmacol Ther201023425726720381630
   PubMed Web of Science ®Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
   PubMed Web of Science ®Google Scholar
• TashkinDPDonohueJFMahlerDAEffects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPDRespir Med2009103451652419208459
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJLJanssensEComparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPDEur Respir J200526221422216055868
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJLJanssensECombining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptomsRespir Med20101047995100420303247
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJLJanssensEEffects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPDChest2006129350951716537846
   PubMed Web of Science ®Google Scholar
• van NoordJABuhlRLaforceCQVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary diseaseThorax201065121086109120978028
   PubMed Web of Science ®Google Scholar
• VogelmeierCKardosPHarariSGansSJStengleinSThirlwellJFormoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month studyRespir Med2008102111511152018804362
   PubMed Web of Science ®Google Scholar
• VogelmeierCFBatemanEDPallanteJEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group studyLancet Respir Med201311516024321804
   PubMed Web of Science ®Google Scholar
• BanerjiDFedeleMJChenHKimHJDual bronchodilation with QVA149 reduces COPD exacerbations: results from the IGNITE program (OS36: COPD 3)Respirol201318S46970
   Google Scholar
• ZhongNWangCZhouXEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol/fluticasone combination (SFC) in patients with COPD: the LANTERN study [abstract]Eur Respir J201444Suppl 58P2815
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD)Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: Updated 2010Seattle, WAGlobal Initiative for Chronic Obstructive Lung Disease (GOLD)2010 Available from: http://www.goldcopd.org/uploads/users/files/GOLDReport_April112011.pdfAccessed February 12, 2014
   Google Scholar
• NanniniLJCatesCJLassersonTJPoolePCombined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20074CD00682917943918
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD)Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: Updated 2014Seattle, WAGlobal Initiative for Chronic Obstructive Lung Disease (GOLD)2014 Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2014_Jan23.pdfAccessed February 15, 2014
   Google Scholar
• RabeKFTimmerWSagkriotisAVielKComparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPDChest2008134225526218403672
   PubMed Web of Science ®Google Scholar
• AgustiAEdwardsLDCelliBECLIPSE InvestigatorsCharacteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohortEur Respir J201342363664623766334
   PubMed Web of Science ®Google Scholar
• DiSantostefanoRLSampsonTLeHVHindsDDavisKJBakerlyNDRisk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic obstructive pulmonary disease: a new-user cohort studyPLoS One201495e9714924878543
   PubMed Web of Science ®Google Scholar
• WeatherallMJamesKClayJDose-response relationship for risk of non-vertebral fracture with inhaled corticosteroidsClin Exp Allergy20083891451145818537983
   PubMed Web of Science ®Google Scholar
• SuissaSKezouhAErnstPInhaled corticosteroids and the risks of diabetes onset and progressionAm J Med2010123111001100620870201
   PubMed Web of Science ®Google Scholar
• CummingRGMitchellPLeederSRUse of inhaled corticosteroids and the risk of cataractsN Engl J Med199733718149203425
   PubMed Web of Science ®Google Scholar
• KimJHParkJSKimKHJeongHCKimEKLeeJHInhaled corticosteroid is associated with an increased risk of TB in patients with COPDChest201314341018102423079688
   PubMed Web of Science ®Google Scholar
• DonaldsonGCSeemungalTAPatelISLloyd-OwenSJWilkinsonTMWedzichaJALongitudinal changes in the nature, severity and frequency of COPD exacerbationsEur Respir J200322693193614680081
   PubMed Web of Science ®Google Scholar
• MahlerDADonohueJFBarbeeRAEfficacy of salmeterol xinafoate in the treatment of COPDChest1999115495796510208192
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBSennSUPLIFT Study InvestigatorsA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
   PubMed Web of Science ®Google Scholar
• FergusonGTAnzuetoAFeiREmmettAKnobilKKalbergCEffect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbationsRespir Med200810281099110818614347
   PubMed Web of Science ®Google Scholar
• WedzichaJACalverleyPMSeemungalTAHaganGAnsariZStockleyRAINSPIRE InvestigatorsThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med20081771192617916806
   PubMed Web of Science ®Google Scholar
• PriceDKeiningerDCosta-ScharplatzMCost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare settingRespir Med2014108121786179325307414
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med20131319920924429126
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMVestboJA novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: the FLAME studyPaper presented at: European Respiratory Society International CongressSeptember 7–11, 2013Barcelona, Spain
   Google Scholar
• DahlRChapmanKRRudolfMSafety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN studyRespir Med2013107101558156723867808
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBTORCH investigatorsSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
   PubMed Web of Science ®Google Scholar
• NewtonMFO’DonnellDEForkertLResponse of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflationChest200212141042105011948031
   PubMed Web of Science ®Google Scholar
• SinghSLokeYKAn overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis2010518919520714372
   PubMedGoogle Scholar
• Van de MaeleBFabbriLMMartinCHortonRDolkerMOverendTCardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patientsCOPD20107641842721166630
   PubMedGoogle Scholar
• WedzichaJADahlRBuhlRPooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patientsRespir Med2014108101498150725135743
   PubMed Web of Science ®Google Scholar
• RidoloEMontagniMRiario-SforzaGGBaroniMIncorvaiaCCombination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safetyTher Adv Respir Dis201592495525691493
   PubMed Web of Science ®Google Scholar
• WeldamSWLammersJWHeijmansMJSchuurmansMJPerceived quality of life in chronic obstructive pulmonary disease patients: a cross-sectional study in primary care on the role of illness perceptionsBMC Fam Pract20141514025087008
   PubMed Web of Science ®Google Scholar